03/27/23 8:00 AMNasdaq : GENE low floatGeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial FibrillationGenetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the US launch of three (3) new diseases taking the totalRHEA-AIneutral
03/13/23 8:00 AMNasdaq : GENE low floatBack-to-back Studies Validate geneType Breast Cancer Risk TestGenetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting theRHEA-AIneutral
02/09/23 8:00 AMNasdaq : GENE low floatNew Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk StratificationGenetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewedRHEA-AIpositive
02/07/23 10:00 AMNasdaq : GENE offeringlow floatGenetic Technologies Announces Closing of $5 Million Registered Direct OfferingGenetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of itsRHEA-AIneutral
02/06/23 8:00 AMNasdaq : GENE low floatGenetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian CancerGenetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update. The innovation and development of this test isRHEA-AIpositive
02/03/23 8:35 AMNasdaq : GENE offeringlow floatGenetic Technologies Announces $5 Million Registered Direct OfferingGenetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered intoRHEA-AIneutral
02/03/23 8:00 AMNasdaq : GENE low floatGENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian CancerGenetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive RiskRHEA-AIneutral
02/01/23 8:00 AMNasdaq : GENE low floatGTG to form Strategic Alliance with global testing leader QIAGENGenetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic allianceRHEA-AIvery positive
01/30/23 8:00 AMNasdaq : GENE low floatQuarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Quarterly business update for the quarter ended 31 DecemberRHEA-AIpositive
01/24/23 8:00 AMNasdaq : GENE low floatGenetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer SymposiumGenetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Spaeth at the prestigiousRHEA-AIpositive